实用肝脏病杂志
實用肝髒病雜誌
실용간장병잡지
JOURNAL OF CLINICAL HEPATOLOGY
2015年
5期
463-467
,共5页
曾阿娟%范春蕾%李磊%张鑫%赵文敏%郑俊福%王征%董培玲%丁惠国
曾阿娟%範春蕾%李磊%張鑫%趙文敏%鄭俊福%王徵%董培玲%丁惠國
증아연%범춘뢰%리뢰%장흠%조문민%정준복%왕정%동배령%정혜국
肝硬化%失代偿期%乙型肝炎%核苷(酸)类似物%肾损害
肝硬化%失代償期%乙型肝炎%覈苷(痠)類似物%腎損害
간경화%실대상기%을형간염%핵감(산)유사물%신손해
Liver cirrhosis%Decompensated%Hepatitis B%Nucleos(t)ide analogues%Kidney injury
目的:评价核苷(酸)类药物(NUCs)对失代偿期乙型肝炎肝硬化患者肾功能的影响。方法纳入失代偿期乙型肝炎肝硬化患者306例,其中接受抗病毒治疗者中包括拉米夫定(LAM)治疗者39例、阿德福韦(ADV)73例、替比夫定(LDT)34例、恩替卡韦(ETV)48例、LAM联合ADV 41例、LDT联合ADV 25例和未抗病毒治疗对照46例。随访3年。排除失访、随访时间小于3年和对照组中途开始抗病毒治疗者97例,最终209例患者纳入本研究。观察估算的肾小球滤过率(eGFR)、血清肌酐和尿素氮水平变化。结果与对照组比,各抗病毒治疗组1年、2年、3年时eGFR较基线均无明显变化(P>0.05),而LDT、LDT联合ADV组eGFR有逐年升高趋势(P>0.05);本组失代偿期乙型肝炎肝硬化患者在基线时存在轻度肾功能损害者58例(27.8%);在存在轻度肾损伤(基线eGFR<90 ml·min-1·1.73m-2)的患者,经LDT或LDT联合ADV治疗3年时患者eGFR复常率分别为55.6%和50%;各组患者血清肌酐和尿素氮水平与基线比无显著性差异(P>0.05)。结论 LDT单药或联合ADV可改善失代偿期乙型肝炎肝硬化患者的肾功能。
目的:評價覈苷(痠)類藥物(NUCs)對失代償期乙型肝炎肝硬化患者腎功能的影響。方法納入失代償期乙型肝炎肝硬化患者306例,其中接受抗病毒治療者中包括拉米伕定(LAM)治療者39例、阿德福韋(ADV)73例、替比伕定(LDT)34例、恩替卡韋(ETV)48例、LAM聯閤ADV 41例、LDT聯閤ADV 25例和未抗病毒治療對照46例。隨訪3年。排除失訪、隨訪時間小于3年和對照組中途開始抗病毒治療者97例,最終209例患者納入本研究。觀察估算的腎小毬濾過率(eGFR)、血清肌酐和尿素氮水平變化。結果與對照組比,各抗病毒治療組1年、2年、3年時eGFR較基線均無明顯變化(P>0.05),而LDT、LDT聯閤ADV組eGFR有逐年升高趨勢(P>0.05);本組失代償期乙型肝炎肝硬化患者在基線時存在輕度腎功能損害者58例(27.8%);在存在輕度腎損傷(基線eGFR<90 ml·min-1·1.73m-2)的患者,經LDT或LDT聯閤ADV治療3年時患者eGFR複常率分彆為55.6%和50%;各組患者血清肌酐和尿素氮水平與基線比無顯著性差異(P>0.05)。結論 LDT單藥或聯閤ADV可改善失代償期乙型肝炎肝硬化患者的腎功能。
목적:평개핵감(산)류약물(NUCs)대실대상기을형간염간경화환자신공능적영향。방법납입실대상기을형간염간경화환자306례,기중접수항병독치료자중포괄랍미부정(LAM)치료자39례、아덕복위(ADV)73례、체비부정(LDT)34례、은체잡위(ETV)48례、LAM연합ADV 41례、LDT연합ADV 25례화미항병독치료대조46례。수방3년。배제실방、수방시간소우3년화대조조중도개시항병독치료자97례,최종209례환자납입본연구。관찰고산적신소구려과솔(eGFR)、혈청기항화뇨소담수평변화。결과여대조조비,각항병독치료조1년、2년、3년시eGFR교기선균무명현변화(P>0.05),이LDT、LDT연합ADV조eGFR유축년승고추세(P>0.05);본조실대상기을형간염간경화환자재기선시존재경도신공능손해자58례(27.8%);재존재경도신손상(기선eGFR<90 ml·min-1·1.73m-2)적환자,경LDT혹LDT연합ADV치료3년시환자eGFR복상솔분별위55.6%화50%;각조환자혈청기항화뇨소담수평여기선비무현저성차이(P>0.05)。결론 LDT단약혹연합ADV가개선실대상기을형간염간경화환자적신공능。
Objective To evaluate the effect of nucleos(t)ide analogues (NUCs) on renal functions in pa-tients with hepatitis B virus(HBV)-induced decompensated liver cirrhosis. Methods In this cohort study,306 pa-tients with HBV-associated decompensated cirrhosis were assigned to receive lamivudine (LAM,n=39),adefovir (ADV,n=73),telbivudine (LDT,n=34),entecavir (ETV,n=48),LDT and ADV (n=41) or LAM and ADV(n=25) treatment for three years,and 46 patients didn’t receive antiviral therapy for control. 97 patients were excluded because of loss,followed-up less than three years,or those in control at baseline received antiviral therapy. 209 patients were followed-up every 3 to 6 months. Changes of estimated glomerular filtration rate (eGFR),serum cre-atinine and urea nitrogen were analyzed. Results Among patients who received antiviral therapy,eGFR levels did not change significantly from baseline (P>0.05),but patients who received LDT or LDT and ADV combination therapy showed gradual increase in eGFR (P>0.05);58 patients (27.8%) had mild kidney function injuries at baseline,and the normalization rates of eGFR in patients with mild renal decrease (eGFR<90 ml·min-1·1.73 m-2) at baseline were 55.6% and 50%,respectively in patients who were treated with LDT or LDT and ADV combina-tion;The serum creatinine and urea nitrogen levels did not obviously change in all patients. Conclusion LDT monotherapy or in combination with ADV is associated with improved renal function in patients with HBV-associ-ated decompensated cirrhosis.